ZyVersa Therapeutics’ CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

February 7, 2024

https://www.globenewswire.com/news-release/2024/02/07/2825165/0/en/ZyVersa-Therapeutics-CEO-Stephen-C-Glover-to-Present-at-the-2024-BIO-CEO-Investor-Conference-to-Provide-Corporate-Update-and-Discuss-Key-Milestones.html

WESTON, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq:ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will provide a corporate update as an invited speaker at the BIO CEO & Investor Conference to be held in New York February 26 – 27, 2024. Mr. Glover will discuss upcoming development milestones for Cholesterol Efflux MediatorTM VAR 200, for which a Phase 2a clinical trial in patients with diabetic kidney disease is planned to begin this quarter, and for Inflammasome ASC Inhibitor IC 100, which is nearing completion of its preclinical program.

Read more at globenewswire.com

Related news for (ZVSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.